Glycine News and Research

RSS

How did SARS-CoV-2 first evolve in humans?

In a perspective article recently published in the journal Science, Hyeryun Choe and Michael Farzan from the Scripps Research Institute, USA, have described the early-stage evolution of SARS-CoV-2 in humans. They have provided a detailed overview of how early mutations in SARS-CoV-2 spike protein facilitate its adaptation in human systems.

7 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

Zipper motif mediates SARS-CoV-2 spike trimerization within host cell membrane

A new preprint research paper posted to the bioRxiv* server describes the results of a nuclear magnetic resonance (NMR) study to determine the structure of the S protein transmembrane domain (TMD) and its membrane-proximal regions.

13 Apr 2021

Novel protein transport system mediates toxin secretion by tuberculosis pathogen

Six years ago, Michael Niederweis, Ph.D., described the first toxin ever found for the deadly pathogen Mycobacterium tuberculosis.

9 Apr 2021

Researchers determine key protein structure that may lead to effective treatments for schizophrenia

Glycine is the smallest amino acid - one of the building blocks of proteins. It acts also as a neurotransmitter in the brain, enabling neurons to communicate with each other and modulating neuronal activity.

7 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

GlyNAC could improve many age-associated defects in older humans

A pilot human clinical trial conducted by researchers at Baylor College of Medicine reveals that supplementation with GlyNAC - a combination of glycine and N-acetylcysteine as precursors of the natural antioxidant glutathione - could improve many age-associated defects in older humans to improve muscle strength and cognition, and promote healthy aging.

29 Mar 2021

Researchers unveil a neuroprotective pathway that suppresses ALS

In general, the RAN proteins are more abundant in the cell nucleus, but in patients with Lou Gehrig's disease, they begin to leak out into the cytoplasm, thereby resulting in abnormal concentration differences.

19 Mar 2021

Structural insights into glycine transporter open new avenues to find effective psychiatric drugs

Glycine can stimulate or inhibit neurons in the brain, thereby controlling complex functions. Unraveling the three-dimensional structure of the glycine transporter, researchers have now come a big step closer to understanding the regulation of glycine in the brain.

4 Mar 2021

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Researchers from the US recently compared antibody binding and viral neutralization against 2 SARS-CoV-2 variants that emerged in different parts of the world. The researchers used sera from spike mRNA vaccinated and naturally infected individuals against a circulating B.1 variant and the emerging B.1.351 variant. The study is published on the preprint server bioRxiv.

24 Feb 2021

Study provides better understanding of metabolic routes involved in regulating satiety

Results of the European study SATIN (SATiety INnovation) reveal a relation between certain metabolites in the blood and the satiety perceived after consuming food.

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Evolution of the spike gene of SARS-CoV-2 for human adaptation

Researchers have found a 96% similarity in nucleotide sequence between bat coronavirus (RaTG13), isolated from Rhinolophus affinis bats in China in 2013, and SARS-CoV-2 and ~97% amino acid similarity with the Spike (S) protein. This S protein performs two essential roles, i.e., mediates receptor-binding and membrane fusion. Hence, spike protein is regarded as a key coronavirus determinant of host tropism.

21 Feb 2021

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

A new preprint research paper posted to the bioRxiv* server shows that these mutations disrupt inhibition by neutralizing antibodies, both natural and therapeutic.

16 Feb 2021

How have new SARS-CoV-2 strains become more transmissible?

A new study discusses the effect of specific mutations on the sensitivity of SARS-CoV-2's spike protein to elastase, and on the intramolecular conformational changes.

22 Jan 2021

Can metabolic biomarkers help clinicians stratify adverse outcome risk in COVID-19 patients?

A recent study describes the alterations in lipids and other parameters that define the state of dysfunctional metabolism in acute COVID-19 illness.

20 Jan 2021

Researchers uncover potential glycine-based treatment for NAFLD

A new study further implicates low levels of the amino acid glycine in development of nonalcoholic fatty liver disease, or NAFLD. It also suggests addressing this might hold the key to a future treatment for the disease.

3 Dec 2020

Argonne supports the largest analysis of COVID-19 genome sequences in the U.S.

Argonne computational resources supported the largest comprehensive analysis of COVID-19 genome sequences in the U.S. and helped corroborate growing evidence of a protein mutation.

5 Nov 2020

An analysis of genetic diversity of D614G mutation in SARS-CoV-2

A new study published in the preprint server bioRxiv in November 2020 reports that the effect of the mutation is minimal, in terms of pathogenicity or altered response to neutralizing antibodies elicited against the native virus strain.

4 Nov 2020

D614G mutation enhances stability of SARS-CoV-2 spike protein

A new study, published on the preprint server bioRxiv in November 2020 by researchers at the Indian Institute of Science, has explored this issue further. The researchers have found that this mutation is associated with structural and energetic changes that cause this spike variant to become more available during infection, thus rendering the associated strain more infective.